Research Partnerships

Molecure is committed to partnering with the world’s leading research institutions in the fight against serious illness. In these partnerships, we seek to leverage our deep scientific expertise in oncology, fibrotic and inflammatory diseases and outstanding capabilities in the discovery and development of small-molecule drugs together with our partners expertise in identifying novel targets and lead compounds to expand and advance our novel small molecule pipeline modulating challenging protein targets with the potential to develop curative treatments.

Out-licensing

Molecure places a significant emphasis on partnering with companies and organizations whose strengths complement its own.

In 2020, Molecure entered into an exclusive, high value partnering deal with Galapagos for OATD-01/GLPG4716, a first-in-class oral CHIT1 inhibitor for idiopathic pulmonary fibrosis (IPF), further validating our strengths in Medicinal chemistry and first/-best-in-class science.

OATD-01/GLPG4716 has shown efficacy in numerous preclinical models of inflammatory and fibrotic diseases and was safe and well tolerated in a first-in-human Phase I clinical trial. It is advancing into a Phase II study in IPF. More information

In-licensing

In March 2022, Molecure entered into an option-to-license agreement with Innovation Partnerships at the University of Michigan to develop novel small molecule inhibitors of an undisclosed target, for the treatment of fibrotic diseases. The novel inhibitors were generated and initially validated as a result of a long-standing research collaboration with Michigan State University (MSU).  More information

This site is registered on wpml.org as a development site.